ClinicalTrials.gg
CompletedNCT04718389NIMBLEUpdated May 18, 2026Results posted

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

A Phase 3 interventional study of GSK3511294 (Depemokimab) and Mepolizumab in Asthma, sponsored by GlaxoSmithKline. Completed at 397 sites in 21 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,717
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.

Enrollment
Largest of 10
1,717 · median 273
Started
2021
with 3 others
Phase 3
7 of 10
3 open now
Registered
2nd of 10
by date
Lead sponsor
10 of 10
GlaxoSmithKline

Among the 10 studies testing depemokimab in Asthma, this one has the largest enrollment, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 2nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About depemokimab

depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing depemokimab in Asthma, or all of them as a file.
02

Study summary

This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • GSK3511294 (Depemokimab)
  • Mepolizumab
  • Benralizumab
  • Interventional
  • Eosinophilic phenotype
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria for study:

  • Adult and adolescent participants more than or equal to (>=)12 years of age, at the time of signing the /assent.
  • Participants who have a documented physician diagnosis of asthma for >=2 years that meets the National Heart, Lung, and Blood Institute guidelines (NHLBI) or Global Initiative for Asthma (GINA) guidelines.
  • Participants receiving either mepolizumab 100 milligrams (mg) or benralizumab 30 mg for >=12 months prior to screening and have a documented benefit to therapy assessed by either:

    (i) >=50% reduction in exacerbation frequency since initiating treatment, or (ii) >=50% reduction in maintenance OCS use since initiating treatment, or (iii) No exacerbations in the past 6 months whilst receiving anti-IL-5/5R therapy and an Asthma Control Questionnaire (ACQ)-5 score of less than or equal to (\<=)1.5 at screening.

  • A well-documented requirement for regular treatment with medium to high dose ICS in the 12 months prior to Visit 1 with or without maintenance OCS. The maintenance ICS dose must be >=440 micrograms (mcg) fluticasone propionate (FP) hydrofluoroalkane (HFA) product daily, or clinically comparable. Participants who are treated with medium dose ICS will also need to be treated with a LABA to qualify for inclusion.
  • Current treatment with at least one additional controller medication, besides ICS [for example (e.g.), LABA, LAMA, leukotriene receptor antagonist (LTRA), or theophylline].

Key exclusion criteria for study:

  • Participants with presence of a known pre-existing, lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis ( other than asthma) or a history of lung cancer.
  • Participants with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly known as Churg-Strauss Syndrome) or Eosinophilic Esophagitis
  • A current or previous history of cancer in remission for less than 12 months prior to screening (Participants that had localized carcinoma of the skin which was resected for cure will not be excluded).
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
  • Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis excluded prior to enrolment.
  • Participants who have received Omalizumab (Xolair), dupilumab (Dupixent) or reslizumab (Cinqair/Cinqaero) within 130 days prior to Visit 1.
  • Participants who have received any Monoclonal antibody (mAb) within 5 half-lives of Visit 1.
  • interval using Fridericia's formula (QTcF) >=450 milliseconds (msec) or QTcF >=480 msec for participants with Bundle Branch Block at screening Visit 1.
  • Current smokers or former smokers with a smoking history of >=10 pack years (number of pack years equal to [number of cigarettes per day/20] times number of years smoked). A former smoker is defined as a participant who quit smoking at least 6 months prior to Visit 1.
  • Participants with allergy/intolerance to a mAb or biologic.

Key exclusion criteria for randomization:

  • Evidence of a clinically significant abnormality in the 12-lead (ECG) over-read conducted at Screening Visit 1, based on the evaluation of the investigator, or QTcF >=450 msec or QTcF >=480 msec for participants with Bundle Branch Block, at randomization Visit 2.
  • Participants with a clinically significant asthma exacerbation in the 7 days prior to randomization should have their randomization visit delayed until the investigator considers the participant's asthma to be stable. If the 8-week screening period has elapsed, then the participant should be considered a run-in failure.
  • Any changes in the dose or regimen of Baseline ICS and/or additional controller medication (except for treatment of an exacerbation) during the run-in period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,717 participants (actual)

Study arms

  • Experimental
    Depemokimab 100mg SC

    Participants received GSK3511294 (Depemokimab) 100 milligrams (mg) subcutaneous (SC) injection administered every 26 weeks (week 0 and week 26) alongside placebo SC treatment matching the active comparator (participant's anti-IL-5/5R treatment prior to randomisation: either placebo matching mepolizumab every 4 weeks or placebo matching benralizumab every 8 weeks).

    Biological: GSK3511294 (Depemokimab) · Biological: Placebo · Drug: Standard of care (SoC) · Device: Pre-filled Syringes (PFS)

  • Active comparator
    Mepolizumab 100 mg / Benralizumab 30 mg SC

    Participants received their existing active comparator (either mepolizumab 100 mg every 4 weeks or benralizumab 30 mg every 8 weeks) according to the participant's treatment prior to randomisation plus placebo SC matching GSK3511294 (Depemokimab) administered every 26 weeks.

    Biological: Mepolizumab · Biological: Benralizumab · Biological: Placebo · Drug: Standard of care (SoC) · Device: Pre-filled Syringes (PFS)

Interventions

  • GSK3511294 (Depemokimab) 100 mg SC along with the placebo and SOC will be administered.

  • BiologicalMepolizumab

    Mepolizumab 100 mg SC will be administered in a single-use PFS.

  • BiologicalBenralizumab

    Benralizumab 30 mg will be administered in a single-use PFS.

  • BiologicalPlacebo

    Placebo will be a sterile liquid formulation.

  • DrugStandard of care (SoC)

    Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).

  • DevicePre-filled Syringes (PFS)

    PFS will include glass barrel with pre-staked needle and plunger.

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Clinically Significant Exacerbations Over 52 Weeks

    Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) \[such as intramuscular (IM), intravenous (IV) or oral\] and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the primary analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.

    Time frame: Up to Week 52

Secondary outcomes

  1. Weighted Mean (WM) Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score

    SGRQ: validated, disease specific questionnaire comprising of 51 questions designed to measure health related quality of life in participants with disease of airway obstruction. It assesses how respiratory symptoms and limitations affect daily life. SGRQ 3 domains: Symptoms, Activity and, Impacts. Each item has an empirically derived weight, and domain scores are combined to produce a total score ranging: 0 to 100. Scores are expressed as a percentage of overall impairment between 100 (worst possible health status) and 0 (best possible health status). Higher scores indicating greater impairment of quality of life. Change from Baseline (CFB): value at indicated time point minus Baseline value. For each participant, WM CFB in SGRQ total score was calculated using linear trapezoidal rule to estimate area under the curve (AUC) from Baseline (Day 1) across Weeks 4, 12, 26, and 52 and presented as a single consolidated SGRQ total score on original scale (i.e., not expressed per unit time).

    Time frame: From Baseline (Day 1) up to Week 52

  2. Weighted Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score

    The ACQ 5 is a validated, 5-item patient reported tool assessing asthma symptoms over the past week. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). Each item is scored from 0 (no impairment) to 6 (maximum impairment), and the final ACQ 5 score is the average of all items, ranging from 0 to 6. Lower scores indicate better asthma control, while higher scores indicate poorer control. CFB was defined as value at the indicated time point minus Baseline value. For each participant, the WM CFB in ACQ-5 score was calculated using the linear trapezoidal rule to estimate the AUC from Baseline (Day 1) across Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48 and 52) and presented as a single consolidated ACQ-5 score on the original scale (i.e., not expressed per unit/time).

    Time frame: From Baseline (Day 1) up to Week 52

  3. Weighted Mean Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)

    Forced Expiratory Volume in One Second (FEV1) is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and was measured by spirometry testing. Change from Baseline in clinic pre-bronchodilator FEV1 was determined. Change from Baseline was defined as value at the indicated time point minus Baseline value. For each participant, the WM change from baseline in FEV1 was calculated using the linear trapezoidal rule to estimate the AUC from Baseline (Day 1) across Weeks 12, 26, 40, and 52). WM change from baseline in FEV1 over 52-week period was presented as a single consolidated data.

    Time frame: From Baseline (Day 1) up to Week 52

07

Results

Posted May 18, 2026

Participant flow

A total of 1717 participants were randomized to the study out of which 1687 participants were included in Full Analysis Set (FAS). FAS population included all randomised participants who received at least one dose of study intervention excluding 27 participants from 4 sites with Good Clinical Practices (GCP) non-compliance/significant data integrity concerns and 3 were randomized in error but did not receive study intervention.

Participant flow — Overall Study
MilestoneDepemokimab 100mg SCMepolizumab 100 mg / Benralizumab 30 mg SC
Started859858
Fas848839
Safety-modified set859855
Completed763772
Not completed9686
Withdrew: Adverse event71
Withdrew: Death01
Withdrew: Lack of efficacy126
Withdrew: Lost to follow-up167
Withdrew: Protocol violation83
Withdrew: Physician decision25
Withdrew: Withdrawal by subject3744
Withdrew: Subject reached protocol defined stopping criteria30
Withdrew: Gcp violation sites1116
Withdrew: No study intervention received03

Outcome measures

PrimaryAnnualized Rate of Clinically Significant Exacerbations Over 52 Weeks

Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) \[such as intramuscular (IM), intravenous (IV) or oral\] and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the primary analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.

Time frame:
Up to Week 52
Reported as:
Least squares mean · Exacerbation per participant per year
Annualized Rate of Clinically Significant Exacerbations Over 52 Weeks
Exacerbation per participant per yearDepemokimab 100mg SCMepolizumab 100 mg / Benralizumab 30 mg SC
Annualized Rate of Clinically Significant Exacerbations Over 52 Weeks0.57 (0.50 to 0.64)0.49 (0.43 to 0.55)
Statistical analysis
  • Depemokimab 100mg SC vs Mepolizumab 100 mg / Benralizumab 30 mg SC · Negative binomial model · p = 0.079 · Rate ratio: 1.16 · 95% CI 0.98 to 1.38
SecondaryWeighted Mean (WM) Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score

SGRQ: validated, disease specific questionnaire comprising of 51 questions designed to measure health related quality of life in participants with disease of airway obstruction. It assesses how respiratory symptoms and limitations affect daily life. SGRQ 3 domains: Symptoms, Activity and, Impacts. Each item has an empirically derived weight, and domain scores are combined to produce a total score ranging: 0 to 100. Scores are expressed as a percentage of overall impairment between 100 (worst possible health status) and 0 (best possible health status). Higher scores indicating greater impairment of quality of life. Change from Baseline (CFB): value at indicated time point minus Baseline value. For each participant, WM CFB in SGRQ total score was calculated using linear trapezoidal rule to estimate area under the curve (AUC) from Baseline (Day 1) across Weeks 4, 12, 26, and 52 and presented as a single consolidated SGRQ total score on original scale (i.e., not expressed per unit time).

Time frame:
From Baseline (Day 1) up to Week 52
Reported as:
Least squares mean · Scores on Scale
Weighted Mean (WM) Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score
Scores on ScaleDepemokimab 100mg SCMepolizumab 100 mg / Benralizumab 30 mg SC
Weighted Mean (WM) Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score-0.69 ± 0.476-0.86 ± 0.486
Statistical analysis
  • Depemokimab 100mg SC vs Mepolizumab 100 mg / Benralizumab 30 mg SC · Negative binomial model · Mean difference (final values): 0.17 · 95% CI -0.85 to 1.20
SecondaryWeighted Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score

The ACQ 5 is a validated, 5-item patient reported tool assessing asthma symptoms over the past week. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). Each item is scored from 0 (no impairment) to 6 (maximum impairment), and the final ACQ 5 score is the average of all items, ranging from 0 to 6. Lower scores indicate better asthma control, while higher scores indicate poorer control. CFB was defined as value at the indicated time point minus Baseline value. For each participant, the WM CFB in ACQ-5 score was calculated using the linear trapezoidal rule to estimate the AUC from Baseline (Day 1) across Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48 and 52) and presented as a single consolidated ACQ-5 score on the original scale (i.e., not expressed per unit/time).

Time frame:
From Baseline (Day 1) up to Week 52
Reported as:
Least squares mean · Scores on Scale
Weighted Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score
Scores on ScaleDepemokimab 100mg SCMepolizumab 100 mg / Benralizumab 30 mg SC
Weighted Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score0.03 ± 0.0260.06 ± 0.026
Statistical analysis
  • Depemokimab 100mg SC vs Mepolizumab 100 mg / Benralizumab 30 mg SC · ANCOVA · Mean difference (final values): -0.03 · 95% CI -0.09 to 0.02
SecondaryWeighted Mean Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)

Forced Expiratory Volume in One Second (FEV1) is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and was measured by spirometry testing. Change from Baseline in clinic pre-bronchodilator FEV1 was determined. Change from Baseline was defined as value at the indicated time point minus Baseline value. For each participant, the WM change from baseline in FEV1 was calculated using the linear trapezoidal rule to estimate the AUC from Baseline (Day 1) across Weeks 12, 26, 40, and 52). WM change from baseline in FEV1 over 52-week period was presented as a single consolidated data.

Time frame:
From Baseline (Day 1) up to Week 52
Reported as:
Least squares mean · Liter
Weighted Mean Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)
LiterDepemokimab 100mg SCMepolizumab 100 mg / Benralizumab 30 mg SC
Weighted Mean Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)-0.014 ± 0.0093-0.018 ± 0.0095
Statistical analysis
  • Depemokimab 100mg SC vs Mepolizumab 100 mg / Benralizumab 30 mg SC · ANCOVA · Mean difference (final values): 0.004 · 95% CI -0.016 to 0.024

Adverse events

Collected over All cause mortality, SAEs and other AEs were collected from signing of Informed Consent (Day -1) up to week 56 (End of follow up).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Depemokimab 100mg SC0/859 (0%)81/859 (9.4%)587/859 (68.3%)
Mepolizumab 100 mg / Benralizumab 30 mg SC1/855 (0.1%)76/855 (8.9%)554/855 (64.8%)
Most frequent serious events
Showing 10 of 135
Most frequent serious events
EventDepemokimab 100mg SCMepolizumab 100 mg / Benralizumab 30 mg SC
AsthmaRespiratory, thoracic and mediastinal disorders19/85912/855
PneumoniaInfections and infestations11/8597/855
COVID-19Infections and infestations7/8594/855
Urinary tract infectionInfections and infestations0/8593/855
InfluenzaInfections and infestations3/8590/855
OsteoarthritisMusculoskeletal and connective tissue disorders3/8591/855
Atrial fibrillationCardiac disorders1/8592/855
Infective exacerbation of asthmaInfections and infestations0/8592/855
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/8592/855
Acute myocardial infarctionCardiac disorders2/8591/855
Most frequent other events
Showing 10 of 19
Most frequent other events
EventDepemokimab 100mg SCMepolizumab 100 mg / Benralizumab 30 mg SC
NasopharyngitisInfections and infestations177/859171/855
COVID-19Infections and infestations157/859143/855
Upper respiratory tract infectionInfections and infestations98/859111/855
CoughRespiratory, thoracic and mediastinal disorders67/85942/855
HeadacheNervous system disorders58/85962/855
SinusitisInfections and infestations57/85950/855
ArthralgiaMusculoskeletal and connective tissue disorders37/85953/855
InfluenzaInfections and infestations50/85938/855
Respiratory tract infectionInfections and infestations47/85939/855
BronchitisInfections and infestations43/85931/855

Baseline characteristics

FAS was defined as all randomised participants who received at least one dose of study intervention excluding participants from sites with GCP non-compliance/significant data integrity concerns.

Age, Continuous
Age, Continuous(YEARS)Depemokimab 100mg SCMepolizumab 100 mg / Benralizumab 30 mg SCTotal
Mean58.3 ± 13.2458.9 ± 13.2458.6 ± 13.24
Sex: Female, Male
Sex: Female, Male(Participants)Depemokimab 100mg SCMepolizumab 100 mg / Benralizumab 30 mg SCTotal
Female5285221050
Male320317637
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Depemokimab 100mg SCMepolizumab 100 mg / Benralizumab 30 mg SCTotal
AMERICAN INDIAN OR ALASKA NATIVE336
ASIAN148140288
BLACK OR AFRICAN AMERICAN263561
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER246
WHITE6596451304
MIXED RACE5510
Other: Unspecified5712
08

Study locations

397 sites
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Scottsboro, Alabama 35768, United States
  • GSK Investigational Site
    Litchfield Park, Arizona 85340, United States
  • GSK Investigational Site
    Phoenix, Arizona 85054, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85251, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Encinitas, California 92024, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Oxnard, California 93036, United States
  • GSK Investigational Site
    Rancho Cucamonga, California 91730, United States
  • GSK Investigational Site
    Redondo Beach, California 90277, United States
  • GSK Investigational Site
    Redwood City, California 94063, United States
  • GSK Investigational Site
    Riverside, California 91786, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    San Diego, California 92307, United States
  • GSK Investigational Site
    Valencia, California 91324, United States
  • GSK Investigational Site
    Woodland, California 95695, United States
  • GSK Investigational Site
    Aurora, Colorado 80238, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80923, United States
  • GSK Investigational Site
    Denver, Colorado 80209, United States
  • GSK Investigational Site
    Wheat Ridge, Colorado 80033, United States
  • GSK Investigational Site
    New Haven, Connecticut 06511, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Clearwater, Florida 33765-2103, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Gainesville, Florida 32610, United States
  • GSK Investigational Site
    Hialeah, Florida 33014, United States
  • GSK Investigational Site
    Hialeah, Florida 33016, United States
  • GSK Investigational Site
    Jacksonville, Florida 32209, United States
  • GSK Investigational Site
    Kissimmee, Florida 34746, United States
  • GSK Investigational Site
    Loxahatchee Groves, Florida 33470, United States
  • GSK Investigational Site
    Miami, Florida 33125, United States
  • GSK Investigational Site
    Miami, Florida 33126, United States
  • GSK Investigational Site
    Miami, Florida 33144, United States
  • GSK Investigational Site
    Miami, Florida 33166, United States
  • GSK Investigational Site
    Miami, Florida 33172, United States
  • GSK Investigational Site
    Miami, Florida 33186, United States
  • GSK Investigational Site
    Miami Lakes, Florida 33014, United States
  • GSK Investigational Site
    Miami Lakes, Florida 33125, United States
  • GSK Investigational Site
    North Palm Beach, Florida 33408, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Orlando, Florida 32819, United States
  • GSK Investigational Site
    Sebring, Florida 33870, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Calhoun, Georgia 30701, United States
  • GSK Investigational Site
    Glenview, Illinois 60077, United States
  • GSK Investigational Site
    Evansville, Indiana 47715, United States
  • GSK Investigational Site
    Overland Park, Kansas 66210, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509, United States
  • GSK Investigational Site
    Owensboro, Kentucky 42301, United States
  • GSK Investigational Site
    Bangor, Maine 04401, United States
  • GSK Investigational Site
    Baltimore, Maryland 21162, United States
  • GSK Investigational Site
    Baltimore, Maryland 21224, United States
  • GSK Investigational Site
    Chevy Chase, Maryland 20815, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Burlington, Massachusetts 01805, United States
  • GSK Investigational Site
    New Bedford, Massachusetts 02740, United States
  • GSK Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48109, United States
  • GSK Investigational Site
    Flint, Michigan 48507, United States
  • GSK Investigational Site
    Warren, Michigan 48088, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55454, United States
  • GSK Investigational Site
    Gulfport, Mississippi 36608, United States
  • GSK Investigational Site
    Jackson, Mississippi 39216, United States
  • GSK Investigational Site
    Chesterfield, Missouri 63017, United States
  • GSK Investigational Site
    Saint Charles, Missouri 63301, United States
  • GSK Investigational Site
    St Louis, Missouri 63110, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68505, United States
  • GSK Investigational Site
    Omaha, Nebraska 68198-5990, United States
  • GSK Investigational Site
    Brick, New Jersey 08724, United States
  • GSK Investigational Site
    Northfield, New Jersey 08225, United States
  • GSK Investigational Site
    Riverdale, New Jersey 07457, United States
  • GSK Investigational Site
    Toms River, New Jersey 08755, United States
  • GSK Investigational Site
    Brooklyn, New York 11215, United States
  • GSK Investigational Site
    Corning, New York 14845, United States
  • GSK Investigational Site
    Great Neck, New York 11040, United States
  • GSK Investigational Site
    New York, New York 60301, United States
  • GSK Investigational Site
    The Bronx, New York 10459-2417, United States
  • GSK Investigational Site
    The Bronx, New York 10467, United States
  • GSK Investigational Site
    Asheville, North Carolina 28803, United States
  • GSK Investigational Site
    Huntersville, North Carolina 28078, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45229, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Corvallis, Oregon 97330, United States
  • GSK Investigational Site
    Altoona, Pennsylvania 15801, United States
  • GSK Investigational Site
    Altoona, Pennsylvania 16601, United States
  • GSK Investigational Site
    Hershey, Pennsylvania 17033, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Wyomissing, Pennsylvania 19610, United States
  • GSK Investigational Site
    Warwick, Rhode Island 02886, United States
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States

Showing the first 100 of 397 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chupp G, Nagase H, Skowasch D, Devouassoux G, Cote A, Jackson DJ, Jackson DJ, Wechsler ME, Imber V, McGinniss JE, O K S, Howarth P, Pavord ID; NIMBLE Study Investigators. Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE). Am J Respir Crit Care Med. 2026 May 1;212(5):921-935. doi: 10.1093/ajrccm/aamag031. PubMed 41738176 ↗
  • Seluk L, Davis AE, Rhoads S, Wechsler ME. Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma. Ann Allergy Asthma Immunol. 2025 Jan;134(1):9-18. doi: 10.1016/j.anai.2024.09.016. Epub 2024 Oct 10. PubMed 39393433 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Sep 2025, 55 months.

Results were first posted in May 2026, 8 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 55 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Jan 22, 2021
StartActual
Jan 26, 2021
Primary completionActual
Sep 14, 2025
CompletionActual
Sep 14, 2025
Results first posted
May 18, 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04718389
Lead sponsor
GlaxoSmithKline
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
Jan 22, 2021
Start date
Jan 26, 2021
Primary completion
Sep 14, 2025
Completion
Sep 14, 2025
Results posted
May 18, 2026
Last update
May 18, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion